Jemincare inks licensing deal for prostate cancer drug with Roche
Genentech will be granted an exclusive license to develop and commercialize the degrader worldwide, and will be fully responsible for the development and commercialization costs.
Genentech will be granted an exclusive license to develop and commercialize the degrader worldwide, and will be fully responsible for the development and commercialization costs.
Subscribe To Our Newsletter & Stay Updated